Welcome to our dedicated page for Nymox Pharm SEC filings (Ticker: NYMXF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nymox Pharmaceutical Corporation (NYMXF) files reports with the U.S. Securities and Exchange Commission as a foreign private issuer, primarily through Form 20-F and Form 6-K. These SEC filings provide official information on the company’s legal matters, corporate developments, and other material events related to its pharmaceutical activities and its drug candidate NYMOZARFEX™ (Fexapotide).
Recent Form 6-K filings from Nymox have reported outcomes of litigation in U.S. and Bahamian courts involving former executives and other parties, including dismissals of complaints with prejudice and awards of costs to the company. Filings have also disclosed court decisions related to actions brought in the Bahamas and in the U.S. District Court for the Central District of California. These documents offer detailed context on disputes that Nymox describes in its news releases.
Nymox’s SEC submissions also confirm its status as a foreign issuer with principal executive offices in Nassau, The Bahamas, and they document matters that can be relevant for shareholders, such as court-ordered payments and other legal resolutions. While the company’s regulatory submissions for NYMOZARFEX to health authorities are not SEC filings, investors can use SEC reports to track how Nymox communicates material events connected to its business and clinical programs.
On this page, NYMXF filings are presented with real-time updates from EDGAR and AI-powered summaries that explain the key points of each document in accessible language. Users can quickly review Form 6-K current reports, annual disclosures on Form 20-F, and other relevant filings, and use AI-generated highlights to understand the significance of legal outcomes, corporate actions, and other reported events without reading every page of the original documents.
Nymox Pharmaceutical Corporation filed a 6-K stating that the U.S. District Court for the Central District of California granted the Company’s and Computershare Investor Services Inc.’s motion to dismiss Christopher Riley’s complaint and dismissed the case, with prejudice.
A dismissal “with prejudice” means the case is closed and cannot be refiled on the same claims. This removes an outstanding legal matter for Nymox without indicating any financial terms. The report was signed on November 7, 2025.
Nymox Pharmaceutical Corporation reported a final court outcome related to its 2023 litigation. The Supreme Court of the Bahamas issued its final order requiring Mr. Lanham, Mr. Riley, CRNSV, and other claimants to pay the Company $203,075.40. This award represents a percentage of expenses previously noted by the Company. The decision provides a defined cash recovery tied to the case and concludes this matter with a court-ordered payment to Nymox.
Nymox Pharmaceutical Corporation reported an insider share purchase. The company disclosed on Form 6-K that its CEO, Dr. Paul Averback, completed the purchase of 102,844 shares on October 20, 2025. The update records the transaction by the company’s chief executive and reflects an increase in his personal share ownership.
Nymox Pharmaceutical Corporation reports favorable developments in two legal matters involving Randall Lanham and related parties. A U.S. District Court in the Central District of California granted the Company’s and Computershare Investor Services Inc.’s motion to dismiss Mr. Lanham’s complaint and dismissed the case with prejudice, meaning it cannot be refiled in that court. Separately, the Registrar for the Supreme Court of The Bahamas held a final hearing in a related case brought by Mr. Lanham, Mr. Riley, CRNSV, and others; that case was withdrawn, and the Registrar awarded costs to the Company. The specific cost details will be reported after the Bahamian Court issues its final Order, which the Company expects soon.